About Northwest Biotherapeutics
Northwest Biotherapeutics is a company based in Bethesda (United States) founded in 1998. It operates as a HealthTech. The company has 25 employees as of December 31, 2024. Northwest Biotherapeutics has completed 2 acquisitions, including Advent BioServices and Flaskworks. Northwest Biotherapeutics offers products and services including DCVax®-L, DCVax®-Direct, and DCVax®-Prostate. Northwest Biotherapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Bethesda, United States
- Employees 25 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Northwest Biotherapeutics, Inc.
-
Annual Revenue
$1.38 M (USD)-28.47as on Dec 31, 2024
-
Net Profit
-$83.78 M (USD)-33.83as on Dec 31, 2024
-
EBITDA
-$64.46 M (USD)-19.88as on Dec 31, 2024
-
Latest Funding Round
$5 M (USD), Post-IPO
Dec 19, 2024
-
Investors
Woodford Investment Management
& 2 more
-
Employee Count
25
as on Dec 31, 2024
-
Investments & Acquisitions
Advent BioServices
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Northwest Biotherapeutics
Northwest Biotherapeutics is a publicly listed company on the OTC with ticker symbol NWBO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Northwest Biotherapeutics
Northwest Biotherapeutics offers a comprehensive portfolio of products and services, including DCVax®-L, DCVax®-Direct, and DCVax®-Prostate.
Personalized vaccine developed for glioblastoma brain cancer treatment.
Vaccine designed for inoperable solid tumor cancer treatment.
Vaccine created for prostate cancer immunotherapy treatment solutions.
People of Northwest Biotherapeutics
Unlock access to complete
Leadership Team
2 people
Software Development Team
2 people
Sales and Marketing
1 people
Manager Team
1 people
Unlock access to complete
Funding Insights of Northwest Biotherapeutics
Investors in Northwest Biotherapeutics
Northwest Biotherapeutics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include Woodford Investment Management, Yorkville Advisors and Schulze Family Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Offers flexible capital to micro-cap and small-cap firms for growth.
|
Locked | Locked | Locked | |
|
Diversified investment portfolios are managed for clients by the firm.
|
Locked | Locked | Locked | |
|
Grants and scholarships are provided by this philanthropic foundation.
|
Locked | Locked | Locked |
Investor details for Northwest Biotherapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Northwest Biotherapeutics
Northwest Biotherapeutics has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Advent BioServices and Flaskworks.
Investment portfolio details for Northwest Biotherapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provides contract development, GMP manufacturing, and ultra-cold storage for cell therapy.
|
Locked | Locked | 2016 | Locked | |
|
Manufacturer of immunotherapeutics for research purpose
|
Locked | Locked | 2016 | Locked |
Complete acquisition details for Northwest Biotherapeutics
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Northwest Biotherapeutics
Detailed financials for Northwest Biotherapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Northwest Biotherapeutics Comparisons
Peer comparison for Northwest Biotherapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Northwest Biotherapeutics
Northwest Biotherapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| Locked | Locked | Locked |
Small molecules are developed for cancer and skin disease treatments.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
Detailed competitors of Northwest Biotherapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Northwest Biotherapeutics
Complete news archive for Northwest Biotherapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Northwest Biotherapeutics
Northwest Biotherapeutics was founded in 1998 and raised its 1st funding round 12 years after it was founded.
Northwest Biotherapeutics is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
As of Dec 31, 2024, the latest employee count at Northwest Biotherapeutics is 25.
Annual revenue of Northwest Biotherapeutics is $1.38M as on Dec 31, 2024.
Northwest Biotherapeutics, Inc. is engaged in the development of personalized cancer vaccines aimed at treating a wide range of solid tumor cancers. The companys proprietary DCVax platform technology utilizes activated dendritic cells to create tailored immunotherapies. Products such as DCVax-L for glioblastoma, DCVax-Direct for inoperable tumors, and DCVax-Prostate for prostate cancer are developed through clinical trials. The focus is placed on advancing cancer treatment solutions within the healthcare and biotechnology sectors.
Northwest Biotherapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
Northwest Biotherapeutics offers DCVax®-L, DCVax®-Direct, and DCVax®-Prostate.
Yes, Northwest Biotherapeutics is publicly traded on OTC under the ticker symbol NWBO.
Northwest Biotherapeutics has made 2 acquisitions, including Advent BioServices, and Flaskworks.
Northwest Biotherapeutics has 3 investors. Key investors include Woodford Investment Management, Yorkville Advisors, and Schulze Family Foundation.
The ticker symbol of Northwest Biotherapeutics is NWBO on OTC.